Author

Ajibola Olagunoye

Observed names: Ajibola O. Olagunoye, Olagunoye, Ajibola O

Observed institutions: Osawatomie State Hospital, Osun State University, Oswego Community Hospital

OpenAlex ID: A5020658669

A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19

2022 · Adeola Fowotade, Folasade Bamidele, et al. · Frontiers in Medicine · 9

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

2021 · Adeniyi Olagunju, Adeola Fowotade, et al. · Trials · 7

PDF

Immunological insights into COVID-19 in Southern Nigeria

2024 · Chinedu A. Ugwu, Oluwasina Alao, et al. · Frontiers in Immunology · 6

Unmet needs, knowledge of contraception and self- reported barriers to contraceptive use among women of reproductive age in Osun State, Nigeria

2026 · Omotayo T. Adigun, Ajibola O. Olagunoye, et al. · International Journal of Reproduction Contraception Obstetrics and Gynecology

PDF

Comparative Study of Modifiable Risk Factors for Cervical Cancer Among Female In-School Adolescents in Osun State

2025 · Adeniran, Elizabeth F, Olagunoye, Ajibola O, et al. · Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria)

Works count: 5

Citation count: 22

H-index: 3

I10-index: